Active Ingredient History
Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Constipation (approved 2008)
Cancer Pain (Phase 3)
Celiac Disease (Phase 4)
Colonic Diseases (Phase 3)
Colonic Neoplasms (Phase 3)
Colonic Polyps (Phase 3)
Colonoscopy (Phase 4)
Colorectal Surgery (Phase 3)
Constipation (Phase 4)
Critical Illness (Phase 3)
Crohn Disease (Phase 4)
Deglutition Disorders (Phase 2)
Depression (Early Phase 1)
Diabetes Mellitus (Phase 2/Phase 3)
Dyspepsia (Phase 1/Phase 2)
Enteral Nutrition (Phase 1/Phase 2)
Esophageal Diseases (Phase 2)
Esophageal Motility Disorders (Phase 4)
Gastric Emptying (Phase 4)
Gastroesophageal Reflux (Phase 4)
Gastrointestinal Hemorrhage (Phase 4)
Gastroparesis (Phase 4)
Healthy Volunteers (Phase 1)
Inflammatory Bowel Diseases (Phase 4)
Intestinal Diseases (Phase 4)
Intestinal Neoplasms (Phase 2)
Intestinal Pseudo-Obstruction (Phase 3)
Intestine, Large (Phase 3)
Irritable Bowel Syndrome (Phase 2/Phase 3)
Liver Diseases (Phase 1)
Opioid-Induced Constipation (Phase 3)
Patient Satisfaction (Phase 4)
Pneumonia, Aspiration (Phase 4)
Postoperative Complications (Phase 4)
Urinary Bladder Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue